Home » Newsletters » BioWorld Science

BioWorld Science

May 3, 2012

View Archived Issues

New phase III results reported on Biogen Idec drug for MS

CO-releasing compound protects against cerebral malaria

Multikinase inhibitor from Piramal Life Sciences significantly suppresses tumor growth

New vasopressin V1B receptor antagonists designed in Japan

Boehringer Ingelheim Pharma develops new CD33-binding antibodies

Novel candidate cancer immunotherapies presented by Oxford BioTherapeutics

Amrita Therapeutics divulges new potential cancer therapies

Second-generation cyclophilin inhibitor selected for clinical development in hepatitis C

Study in Chinese children links LINE-1 methylation to congenital heart defect

Advanced Cell Technology confirms additional site for dry AMD stem cell trial

AVEO reports preliminary data from phase II ficlatuzumab combination trial

Zogenix submits NDA for Zohydro

BioAnalytica discloses novel HSP 90-targeting antibodies

Trevena enters collaboration to identify novel biased ligand molecules

Altor BioScience product to enter clinical testing for melanoma

Kyowa Hakko Kirin offers development update for first quarter 2012

Cleveland BioLabs and Incuron receive clearance for CBLC-137 trial in Russia

Quark to conduct phase IIa study of siRNA drug in open-angle glaucoma

Enrollment complete in pivotal study of oral testosterone replacement therapy

Ultragenyx reports first-in-human data on UX-001

SUMMACTA study meets primary endpoint

Genomic Health and OncoMed form alliance

Dako and Genentech to collaborate on U.S. regulatory submissions for companion diagnostics

Azelon completes phase II study of nasal spray for osteoporosis

Janssen seeks approval of Xarelto for additional indications

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...